Waxman AJ, et al. - This work was planned to assess the incidence of carfilzomib-associated cardiovascular adverse events (CVAE). In addition, researchers here compared the rates of carfilzomib CVAE among different doses and companion therapies. They observed a high rate of clinically significant CVAEs in association with carfilzomib. Findings, thereby, highlighted the necessity for increased awareness of these adverse events and further study into optimal patient selection and risk mitigation strategies.